References
- Saller DN, Canick JA. Current methods of prenatal screening for Down screening for Down syndrome and other fetal abnormalities. Clin Obstet Gynecol 2008;51:24–36.
- Royal College of Obstetricians and Gynaecologists. Amniocentesis and chorionic villus sampling. Evidence-based Guidelines No. 8, 2005.
- Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, et al First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001–2011.
- ACOG Committee on Practice Bulletins. ACOG Practice Bulletins No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007;109:217–227.
- Ekelund CK, Jorgensen FS, Petersen OB, Sundberg KS, Tabor A. Danish Fetal Medicine Research Group. Impact of a new national screening policy for Down's syndrome in Denmark: population based cohort study. BMJ 2008;337:a2547.
- Hadlow NC, Hewitt BG, Dickinson JE, Jacoby P, Bower C. Community-based screening for Down's syndrome in the first trimester using ultrasound and maternal serum biochemistry. Br J Obstet Gynaecol 2005;112:1561–1564.
- O'Leary P, Breheny N, Dickinson JE, Bower C, Goldblatt J, Hewitt B, Murch A, Stock R. First-trimester combined screening for Down syndrome and other fetal anomalies. Obstet Gynecol 2006;107:869–876.
- Soergel P, Pruggmayer M, Schwerdtfeger R, Muhlhaus K, Scharf A. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11–14 weeks: a regional experience from Gemany. Fetal Diagn Ther 2006;21:264–268.
- Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. Br J Obstet Gynaecol 2003;110:281–286.
- Stenhouse EJ, Crossley JA, Aitken DA, Brogan K, Cameron AD, Connor JM. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice. Prenat Diagn 2004;24:774–780.
- Schielen PC, van Leeuwen-Spruijt M, Belmouden I, Elvers LH, Jonkers M, Loeber JG. Multi-centre first-trimester screening for Down syndrome in the Netherlands in routine clinical practice. Prenat Diagn 2006;26:711–718.
- Wray AM. Ghidini A, Alvis C Hodor J, Landy HJ, Poggi SH. The impact of first-trimester screening on AMA patients' uptake of invasive testing. Prenat Diagn 2005;25:350–353.
- Grant SS. Options for Down syndrome screening: what will women choose? J Midwifery Womens Health 2005;50:211–218.
- Zoppi MA, Ibba RM, Putzolu M, Floris M, Monni G. Nuchal translucency and the acceptance of invasive prenatal chromosomal diagnosis in women aged 35 and older. Obstet Gynecol 2001;97:916–920.
- Chasen ST, McCullough LB, Chervenak FA. Is nuchal translucency screening associated with different rates of invasive testing in an older obstetric population? Am J Obstet Gynecol 2004;190:769–774.
- Lam YH, Lee CP, Sin SY, Tang R, Wong HS, Wong SF, Fong DY, Tang MH, Woo HH. Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome. Prenat Diagn 2002;22:730–735.
- Morries JK, Mutton DE, Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 2002;9:2–6.
- Bray IC, Wright DE. Estimating the spontaneous loss of Down syndrome fetuses between the times of chorionic villus sampling, amniocentesis and live birth. Prenat Diagn 1998;18:1045–1054.
- Breathnach FM, Maone FD, Lambert-Messerlian G, Cuckle HS, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Klugman S, et al First- and second-trimester screening: detection of aneuploidies other than Down syndrome. Obstet Gynecol 2007;110:651–657.